CHThe Swiss pharmaceutical company Galderma has seen increased demand for its bio-stimulators, which are used to combat sagging skin caused by weight loss treatments like Ozempic. This surge in interest has contributed to Galderma's rise in the Swiss Market Index (SMI). The article highlights how the growing popularity of these products is benefiting the company financially.
Bias read (Center): The article provides a factual overview of market trends affecting a pharmaceutical company without taking a clear stance or using biased language. It focuses on economic developments rather than political controversy.
